title: Optimal management of resectable gastric adenocarcinoma.
abstract: The worldwide incidence of gastric adenocarcinoma has rapidly declined in the past century, but gastric cancer remains the fifth most common malignancy in the world. Approximately half of all cases of gastric cancer are diagnosed in Eastern Asia. In this review, we provide an overview of the landmark studies investigating neoadjuvant and adjuvant therapies in resectable gastric cancer and highlight ongoing efforts to define optimal population-adapted management strategies.
authors.affiliation: Department of Radiation Oncology at Dana Farber Cancer Institute/Brigham and Women's Hospital, Harvard Radiation Oncology Program, 75 Francis Street, Boston, MA 02215, USA.
authors.forename: Daniela L
authors.initials: DL
authors.lastname: Buscariollo
authors.forename: Harvey J
authors.initials: HJ
authors.lastname: Mamon
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods; D013274:Stomach Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*
keywords: chemoradiation; chemotherapy; gastric adenocarcinoma; locally advanced; multimodality therapy; radiation therapy; respectable; stomach cancer